Sotabase

Career

· Data Engineer II, AEON Bank2025–
· Senior Data Scientist, Google2025–
· Data Analyst, Senior Executive, AEON Bank2023–2024
· Data Science Fellow, D-Lab @ Berkeley2022–
· Data Analyst, DoctorOnCall2022–
· Data Science Instructor, Forward School2022–2023
· Data Analyst Intern, Setel Ventures2021–
· Data Science & Visualisation, DataCamp2019–

Publications (69)

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Journal of Clinical Oncology · 2022
516
cited
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10‐year update and subset analysis
Cancer · 2015
193
cited
Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression
Nature Communications · 2016
178
cited
Revisiting neoadjuvant therapy in non-small-cell lung cancer.
The Lancet Oncology · 2021
142
cited
Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window
British Journal of Ophthalmology · 2002
123
cited
Lung Cancer Screening in Asia: An Expert Consensus Report.
Journal of Thoracic Oncology · 2023
107
cited
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
JTO Clinical and Research Reports · 2022
101
cited
Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasis
Nature Communications · 2023
80
cited
Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.
2013
70
cited
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers
JCO Precision Oncology · 2022
66
cited
Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth
British Journal of Ophthalmology · 2002
66
cited
Single‐cell profiling approaches to probing tumor heterogeneity
International Journal of Cancer · 2016
55
cited
Intertumor heterogeneity of non‐small‐cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics
International Journal of Cancer · 2014
47
cited
Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.
2021
46
cited
Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls
Journal of Thoracic Oncology · 2016
43
cited
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
Journal of Clinical Oncology · 2023
38
cited
Inferring cancer disease response from radiology reports using large language models with data augmentation and prompting
J. Am. Medical Informatics Assoc. · 2023
35
cited
KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology · 2023
34
cited
Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
PLoS ONE · 2015
33
cited
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
Nature Medicine · 2023
31
cited
Sotabase